Clinical Trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Protocol Amendment History 6 changes
critical Primary endpoint(s) modified 2026-07-10
notable Enrollment increased: 208 -> 262 participants 2026-07-10
minor Trial arms changed: 6 -> 9 2026-07-10
notable Trial sites reduced: 39 -> 13 locations 2026-07-10
notable Primary completion pushed: 2029-05 -> 2029-07 2026-07-10
minor Completion pushed: 2029-05 -> 2029-07 2026-07-10
Trial Details
NCT Number NCT07174583
Lead Sponsor IDEAYA Biosciences
Conditions Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
Enrollment 262 participants
Start Date 2025-10-14
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-09